Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entresto Hurdles Dog Novartis

This article was originally published in Scrip

Executive Summary

Entresto's slow market start following its US approval prompted many questions as Novartis AG reported its quarterly results Oct. 27. The heart failure drug booked sales of $16m in third quarter following FDA approval on July 7, 2015, and the company acknowledged that its current lack of reimbursement status for Medicare Part D patients – which make up a large part of its target population – was holding it back. By way of contrast, sales for psoriasis drug Cosentyx (secukinumab), which was approved in the US in January, were $88m in the third quarter.

Advertisement

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC030166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel